Adult digital-health review frameworks ask reasonable questions: Is the content accurate? Does the product escalate safely? Is the data handled properly? Applied to a children’s product, those questions are necessary — and nowhere near sufficient. A paediatric app has two users at once (a child and a parent), a patient whose risks change with age in months rather than decades, and consent arrangements that involve a third party acting for someone who cannot consent for themselves. This article sets out a practical, seven-part review framework founders and product teams can run before launch — and re-run after it.
Table of Contents
- Why adult frameworks fail children
- The seven-part review framework
- Worked examples: what recent paediatric AI funding is actually buying
- Founder checklist
- What a review is — and is not
- Frequently asked questions
Why adult frameworks fail children
Three structural differences break adult assumptions. First, development: a recommendation that is safe for a ten-year-old may be unsafe for a ten-month-old, so content that is not age-banded is not finished. Second, the reader: parents interpret observable signs on behalf of a child who may not be able to describe symptoms, so wording has to name what a parent can actually see and count. Third, consent and safeguarding: data is collected about a child, usually entered by an adult, sometimes in a household where the adult entering it is not the only person with access to the device. Our earlier piece on seven paediatric risks adult-focused digital-health teams commonly miss covers these patterns in depth; the framework below turns them into reviewable checks.
The seven-part review framework
1. Clinical accuracy and age-banding
Check every clinical statement against current evidence — then check it again by age band. Record, for each content set, the age range it applies to, the source it was drawn from, and the date it was last reviewed. A statement with no age range and no review date should fail this section outright.
2. Escalation and red-flag handling
Test the product with the presentations a worried parent will actually type at 2 a.m., including misspellings, partial descriptions and the red flags themselves entered as ordinary questions. The product must recognise red flags, stop routine advice, and give a specific route into care with a time frame. We set out the testing method in how to review red-flag and escalation advice in a symptom checker.
3. Communicating uncertainty to parents
Parents need to know what is known, what is not yet known, and what would change the advice. Vague reassurance (“it is probably nothing”) and vague alarm (“seek help if worried”) both fail. Our guide to writing patient information that communicates uncertainty safely gives wording patterns that hold up under review.
4. Data, consent and safeguarding
Map what data the product collects about the child, who can see it, how consent is obtained and withdrawn, and how long records are kept. Then test the uncomfortable cases: a shared family device, a separated household, a teenager who needs a degree of confidentiality, and a safeguarding concern disclosed in free text. If the product has no defined route for that last case, it is not ready.
5. Usability for parent and child shared use
Test with the real pair of users: a tired parent holding a phone in one hand, and, where the child interacts directly, a child of the youngest age in the target range. Check reading level, language options, and whether safety-critical actions (escalation, contacting a clinician) remain reachable when the user is stressed and skimming.
6. Medication and dosing safety, where relevant
If the product touches medication at all — reminders, adherence tracking, dose information — weight-based dosing, maximum doses and age cut-offs need explicit checks, and any calculated figure should show its working and its source. A fluent, confident dose statement with no traceable basis is one of the most serious findings a review can make.
7. Post-launch monitoring and the incident path
A launch review goes stale. Define, before launch: who reads user feedback and safety reports, how quickly, what triggers a content change or a product pause, and how incidents are recorded. Teams can run the free Chatbot Safety Self-Check first to see where escalation, uncertainty language and safeguarding stand before a full review.
Worked examples: what recent paediatric AI funding is actually buying
In October 2026, Amazon Web Services reported awarding more than $1.8 million in cash and cloud credits to 11 organisations, including five children’s hospitals, through its Children’s Health Innovation Award (all figures AWS-reported). The projects are useful worked examples of this framework in action — they are briefed examples reported by AWS, not products we have tested.
- Traceability as a requirement (framework parts 1 and 2). Lurie Children’s Intelligent Chart Assist turns outside records into clinician-ready summaries in which every extracted fact links back to its source. The review lesson: test source-linking accuracy before summary fluency. A summary that reads well but cannot be traced is not reviewable.
- Data readiness before models (part 4). Seattle Children’s and Cook Children’s are using grant funding to build unified, AI-ready platforms combining EHR, EEG, imaging and genomic data for epilepsy work. The money is buying plumbing before algorithms — a reminder that data quality, consent and access control are reviewed first, not last.
- A prediction must end in a workflow (parts 2 and 7). Children’s Hospital of The King’s Daughters pairs real-time prediction of medication non-adherence with care-team alerts and reminders. A risk score needs an owner, a timing rule and an escalation path; without them, the prediction is unfinished work.
- Faster diagnosis still needs a safety net (part 3). Nationwide Children’s is extending a machine-learning platform that has cut time to genetic diagnosis for critically ill infants. Speed under time pressure raises the stakes on uncertainty language and on a clinician override that is faster than accepting the output.
Founder checklist
| Check | Pass looks like |
|---|---|
| Age-banding | Every clinical statement carries an age range, a source and a review date |
| Red-flag tests | A written test set, including misspelled and partial entries, with recorded results |
| Uncertainty wording | Named signs, time boundaries and actions — no bare reassurance or bare alarm |
| Consent and safeguarding | A data map, a withdrawal route, and a defined safeguarding path tested end to end |
| Shared-use testing | Safety actions reachable by a stressed parent and, where relevant, the youngest target child |
| Medication safety | Weight-based checks, maximum doses and sources shown wherever dosing appears |
| Monitoring | A named owner, a review rhythm and an incident log that exists before launch day |
What a review is — and is not
This framework is clinical-content and product-safety review: it checks what a product says and does against evidence and good practice. It is not regulatory approval, certification, or a guarantee that a product is safe. Whether a product needs regulatory assessment, and under which framework, is a separate question for qualified regulatory advisers. A review can find a product wanting; it cannot approve one.
Frequently asked questions
What should a pediatric app review check first?
Age-banding and escalation. Check that every clinical statement states the age range it applies to, carries a source and a review date, and that red-flag presentations reliably stop routine advice and route the parent to care with a time frame. If either fails, later polish does not matter.
How is pediatric review different from adult digital-health review?
Three ways: risk changes rapidly with age, so content must be age-banded; the reader is usually a parent interpreting signs on the child’s behalf, so wording must name observable signs; and consent and safeguarding involve a third party acting for a patient who cannot consent for themselves.
Who should do the review — clinician, UX, or regulator?
Different parts need different reviewers. Clinical accuracy, escalation and dosing need clinical review; shared parent-and-child use needs usability testing with real users; regulatory assessment is a separate legal process done by qualified regulatory advisers. No single reviewer covers all three.
What evidence should founders prepare before a review?
A content inventory with sources and review dates, the age bands the product targets, red-flag test results, a data and consent map, any medication logic with its sources, and the post-launch monitoring and incident process. Arriving with these in hand makes a review faster and considerably more useful.
Building a healthcare-AI or pediatric digital-health product? DigitalProved provides an independent review of clinical content, patient-safety risks, escalation advice and user communication. Receive a prioritised written report and recorded walkthrough within five working days. Request a Product Review
